CAS: 374703-78-3

PKG drug G1 targets PKG Iα C42. PKG drug G1 can couple to vasodilation and blood pressure lowering by a C42 PKG Iα-independent mechanism.

PKG drug G1 is a synthetic small-molecule inhibitor, which is a laboratory-engineered compound designed to interfere with the signaling pathways involved in cell cycle regulation. It is specifically sourced through chemical synthesis, allowing for precise modifications to enhance its stability and efficacy in cellular systems. The mode of action of PKG drug G1 involves selectively targeting and inhibiting certain protein kinases that play a crucial role in the progression of the cell cycle, particularly the G1 phase. By inhibiting these kinases, the drug effectively halts cell division, making it a potential candidate for research in cancer treatment. In scientific applications, PKG drug G1 is primarily used in oncology research to study its effects on cellular proliferation and tumorigenesis. By analyzing its impact on various cancer cell lines, researchers aim to elucidate its potential for development into a therapeutic agent. Furthermore, its specificity and mechanism of action offer insights into the fundamental processes of cell cycle control, contributing to broader fields of cancer biology and molecular medicine.

PKG drug G1